Plain-English translation of NCT05918861 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help people who have recently had a heart attack and have a certain genetic trait. Researchers will compare the medication to a placebo (a dummy pill with no active drug) to see which group has fewer heart-related events over time. This is a large, carefully controlled study involving about 2,000 people.
Many people survive a heart attack but remain at risk for future heart problems. This trial is exploring whether this new treatment can provide additional protection beyond standard heart disease medications, particularly for people with this specific genetic background.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the new medication or a placebo pill once daily. You'll have check-in visits every three months, which can be done virtually when possible or in-clinic. The study will continue until enough participants have experienced heart-related events for researchers to determine if the medication works—this could take several years. Even if you stop taking the medication early, researchers will continue to check on your health every three months to track outcomes.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States